Susan E. Pratt - Concepedia

Author

Susan E. Pratt

Eli Lilly (United States)

Also Known As

Pratt, Susan E., S E Pratt, S. Pratt, S.E. Pratt, SUSAN E. PRATT, Susan E Pratt, Susan E. Pratt, Susan Pratt

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)McGill University Jewish General Hospital

About

Susan E. Pratt is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	13	897
2	Natural Sciences	6	6	387
3	Public Health	2	2	83
4	Engineering	1	1	10
5	Health Sciences	1	1	17

Susan E. Pratt

Publications

1.3K

Citations

H-Index

Page 1

	Year	Citations
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites Susan E. Pratt, Robert L. Shepard, Ramani A. Kandasamy, Molecular Cancer Therapeutics Antibiotic ResistanceCancer BiologyTumor BiologyDrug ResistanceMolecular Pharmacology	2005	260
Selectivity of the Multidrug Resistance Modulator, LY335979, for P-Glycoprotein and Effect on Cytochrome P-450 Activities Anne H. Dantzig, Robert L. Shepard, K L Law, Journal of Pharmacology and Experimental Therapeutics	1999	178
Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Susan E. Pratt, Michaël Pollak PubMed Tumor BiologySpecific AlterationsSeveral IgfbpsBreast OncologyEndocrine-related Cancer	1993	120
Expression of multidrug resistance‐associated protein 2 (MRP2) in normal human tissues and carcinomas using tissue microarrays George E. Sandusky, Karen Mintze, Susan E. Pratt, Histopathology	2002	118
Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity Robert M. Campbell, Bryan D. Anderson, Nathan A. Brooks, Molecular Cancer Therapeutics Drug TargetAntitumor ActivityP38 MapkPharmacotherapyCancer Biology	2013	115
Human Carboxylesterase-2 Hydrolyzes the Prodrug of Gemcitabine (LY2334737) and Confers Prodrug Sensitivity to Cancer Cells Susan E. Pratt, Sara Durland-Busbice, Robert L. Shepard, Clinical Cancer Research	2013	100
Insulin-like Growth Factor Binding Protein 3 (IGF-BP3) Inhibits Estrogen-Stimulated Breast Cancer Cell Proliferation Susan E. Pratt, Michaël Pollak Biochemical and Biophysical Research Communications Breast OncologyGrowth HormoneHuman GrowthCancer GrowthBreast Cancer	1994	71
Clinical Inertia: A Common Barrier to Changing Provider Prescribing Behavior Christianne L. Roumie, Tom A. Elasy, Kenneth A. Wallston, The Joint Commission Journal on Quality and Patient Safety Family MedicineBehavioral MedicinePreventive MedicineHealth PolicyClinical Inertia	2007	67
LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer Eliza Vakana, Susan E. Pratt, Wayne Blosser, Oncotarget PathologyCancer BiologyTumor BiologyBrafmut MelanomaReceptor Tyrosine Kinase	2016	66
Kinetic validation of the use of carboxydichlorofluorescein as a drug surrogate for MRP5-mediated transport Susan E. Pratt, Victor Chen, William I. Perry, European Journal of Pharmaceutical Sciences Medicinal ChemistryPharmaceutical ScienceMrp5-mediated TransportBiochemistryMedicine	2005	49

Page 1